Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.
about
Oxygen sensing in retinal health and diseaseMolecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseasesGene expression microarray analysis of early oxygen-induced retinopathy in the ratProlyl hydroxylase domain protein 2 (PHD2) mediates oxygen-induced retinopathy in neonatal miceHyperoxia exposure impairs nephrogenesis in the neonatal rat: role of HIF-1α.Stimulating retinal blood vessel protection with hypoxia-inducible factor stabilization: identification of novel small-molecule hydrazones to inhibit hypoxia-inducible factor prolyl hydroxylase (an American Ophthalmological Society thesis).Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration.The Small Molecule R-(-)-β-O-Methylsynephrine Binds to Nucleoporin 153 kDa and Inhibits Angiogenesis.A comparing study of quantitative staining techniques for retinal neovascularization in a mouse model of oxygen-induced retinopathySildenafil attenuates vaso-obliteration and neovascularization in a mouse model of retinopathy of prematurity.Hypoxia-induced angiogenesis: good and evilAnti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathyComparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity.Role of hypoxia-inducible factor-1α in preconditioning-induced protection of retinal ganglion cells in glaucoma.Hematological, hepatic, and retinal phenotypes in mice deficient for prolyl hydroxylase domain proteins in the liverMediators of ocular angiogenesis.Hypoxia-inducible factor (HIF) and HIF-stabilizing agents in neonatal care.Mechanisms and management of retinopathy of prematurity.Prolyl 4-hydroxylases, master regulators of the hypoxia response.Pathophysiology and mechanisms of severe retinopathy of prematurity.VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesisAdvances in understanding and management of retinopathy of prematurity.von Hippel-Lindau protein regulates transition from the fetal to the adult circulatory system in retina.VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression.Signaling pathways triggered by oxidative stress that mediate features of severe retinopathy of prematurity.2-Methoxyestradiol confers neuroprotection and inhibits a maladaptive HIF-1α response after traumatic brain injury in mice.Hypoxia and hypoxia inducible factor-1α are required for normal endometrial repair during menstruation.Lack of P4H-TM in mice results in age-related retinal and renal alterations.Low urine vascular endothelial growth factor levels are associated with mechanical ventilation, bronchopulmonary dysplasia and retinopathy of prematurity.The progress of prophylactic treatment in retinopathy of prematurity.Tubular immaturity causes erythropoietin-deficiency anemia of prematurity in preterm neonates.
P2860
Q26827518-1C9AF127-0F65-4C7A-82CA-2F0B6A10D1CBQ28297656-9A353FED-FB67-4196-92BF-27FEBEEF622DQ28577253-431050BD-E813-4AE2-988E-5DA93559774AQ34805681-4C9856D6-A2BF-4D43-8AD6-FDD089ED7780Q35072751-50D7DDD0-9B80-44C6-AB67-11F9945B12DCQ35079777-D49738DF-DD34-497D-B3D6-E42D0C2116AEQ35247687-84F5BCFA-8CF7-412E-87CF-883C97C05D0BQ35721891-FCEE1296-BA99-416A-9EBF-8DAAE1A296CCQ35924250-2BEEE6F8-5343-4D29-872E-7091489EBA4CQ36103389-ECA73971-7619-477B-A883-3C9053E87BBBQ36137705-DD29DD96-FB65-4563-8998-F1654A5AEAFEQ36379513-A24C6302-1EA1-4F91-A33D-FE182B7D23A4Q37173066-426D2201-F690-4088-B7EE-2B4C0F1B585FQ37363949-B7E2D432-DF0B-4C96-8E22-6577E2E38BCEQ37672906-AF3ED146-E893-48C4-8FD7-A0BF785E4D53Q37678807-C713BA39-C97A-4628-8B1A-DA552FDC1CB2Q37769765-228021D5-45F0-4B27-B4D3-486B4B0EB280Q38069895-E8FCCE33-D8E0-49F6-A366-8832589C316BQ38089239-40BFC120-3870-405A-BE3E-2640303CB9F6Q38274655-5D9C3744-7326-4EB5-9D41-97679A91E3B1Q38560836-DC463B7B-E9D4-4FDA-883D-9CB4CFA998EEQ39052915-5893F7BB-64AD-42B5-AE0C-3AAA7CAD760EQ39404350-47AE2641-96DF-444B-B3D7-FC01E94126A2Q42044757-229EBD17-3124-412B-BC67-D3EFE02547CDQ42081421-D94AF8BE-865A-464D-9CC6-15CDE2A1EDACQ45177122-691473DD-B376-4543-B2A4-F3E13E1A7B57Q48181401-DE0E493C-4F32-4F19-B07B-044EE3752CA0Q48599721-76C80578-72D3-4367-A922-8E155F878E6DQ50957382-79EF08C9-2C7F-497F-AA3B-C7F3556B22A6Q54999086-A7F969C7-597B-46B3-88C3-F759C58CEF0BQ55318516-F48D0882-480C-46D5-9D04-4FDEDB16C341
P2860
Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.
@en
Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.
@nl
type
label
Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.
@en
Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.
@nl
prefLabel
Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.
@en
Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.
@nl
P2093
P2860
P356
P1476
Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.
@en
P2093
Bela Anand-Apte
George Hoppe
Jonathan E Sears
Quteba Ebrahem
P2860
P304
19898-19903
P356
10.1073/PNAS.0805817105
P407
P577
2008-12-04T00:00:00Z